Skip to main content
. Author manuscript; available in PMC: 2012 Nov 26.
Published in final edited form as: Toxicol Lett. 2010 Sep 22;199(3):261–268. doi: 10.1016/j.toxlet.2010.09.008

Fig 3. BRCA1 modulates BPA-induced ERα target gene expression.

Fig 3

(A) MCF7 cells pre-treated with 100 nM siRNA (control vs. BRCA1) as in Fig. 1 were treated with various doses of BPA for 24 h. Upper panel: the expression levels of proteins were analyzed by western blot using anti-BRCA1, anti-progesterone receptor (PR), anti-pS2, anti-PCNA, and anti-β-actin antibodies in total cell lysates. Lower panel: densitometric analyses of western blot. For each gene, we conducted two-way ANOVA instead of one-way ANOVA, one factor is BRCA1-siRNA vs. control-siRNA and the other factor is different concentration of BPA treatment groups. BRCA1: F=19.83, p<0.0001 Group F=76.4 p<0.0001, BPA treatment F=0.98 p=0.4152. PR: F=66.63, p<0.0001 Group F=42.98 p<0.0001, BPA treatment F=74.52 p<0.0001. pS2: F=10.78, p<0.0001 Group F=15.24 p<0.0004, BPA treatment F=9.29 p=0.0001. PCNA: F=8.77, p<0.0001 Group F=24.55 p=0.0004, BPA treatment F=3.51 p=0.023. (B) The levels of mRNA expression were analyzed by gene-specific primers for PR or pS2. Total RNA harvested from the cells treated as in (A) was used for quantitative real-time PCR as described in 2.3. PR: F=17.85, p<0.0001 Group F=26.43 p=0.0003, BPA treatment F=19.98 p=0.0003. Tukey test demonstrated significant differences between groups 1 vs. 3, 2 vs. 3, 1 vs. 4, and 2 vs. 4 (see Fig. 1 for the description of group 1 to 4). However, the differences in groups 1 vs. 2 and 3 vs. 4 were not significant. pS2: F=22.55, p<0.0001 Group F=24.72 p=0.0004, BPA treatment F=21.83 p<0.0001. Tukey test results were significant between groups 1 vs. 3, 2 vs. 3, 1 vs. 4, and 2 vs. 4. But, there were no statistical differences were found between groups 1 vs. 2 and 3 vs. 4.